NEEDHAM, Mass. — September 17, 2025 — Leads & Copy — Candel Therapeutics, Inc. (Nasdaq: CADL) will present data from its phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco, CA, from September 27 to October 1, 2025.
The abstract has been selected for inclusion in ASTRO’s Science Highlights – Genitourinary Cancer session on Sunday, September 28 at 8:00 a.m. PT.
CAN-2409 is the lead product candidate from Candel’s adenovirus platform. The company recently completed a pivotal, placebo-controlled, phase 3 clinical trial of CAN-2409 in localized prostate cancer, which achieved the primary endpoint supported by secondary endpoints.
Candel also reported successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The FDA granted Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer.
CAN-3110, the lead product candidate from the HSV platform, is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma.
Investor Contact: Theodore Jenkins, Vice President, Investor Relations and Business Development, Candel Therapeutics, Inc., tjenkins@candeltx.com
Media Contact: Ben Shannon, Vice President, ICR Healthcare, CandelPR@icrhealthcare.com
Source: Candel Therapeutics, Inc.
